potential inhibitors of the otub1 catalytic site to develop an anti-cancer drug using in-silico approaches

Background: cancer continues worldwide. it has been reported that otub1, a cysteine protease, plays a critical role in a variety of tumors and is strongly related to tumor proliferation, migration, and clinical prognosis by its functions on deubiquitination. drug advances continue against new therapeutic targets. in this study we used otub1 to develop a specific pharmacological treatment to regulate deubiquitination by otub1. the aim of this research is to regulate otub1 functions.methods: by molecular docking in a specific potential otub1 interaction site between asp88, cys91, and his26 amino acids, using a chemical library of over 500,000 compounds, we selected potential inhibitors of the otub1 catalytic site.results: ten compounds (ot1 - ot10) were selected by molecular docking to develop a new anti-cancer drug to decrease otub1 functions in cancer processes.conclusions: ot1 – ot10 compounds could be interacting in the potential site between asp88, cys91, and his265 amino acids in otub1. this site is necessary for the deubiquitinating function of otub1. therefore, this study shows another way to attack cancer.